Projects per year
Abstract
Chronic hyperglycemia induces intrarenal oxidative stress due to the excessive production of reactive oxygen species (ROS), leading to a cascade of events that contribute to the development and progression of diabetic kidney disease (DKD). NOX5, a pro-oxidant NADPH oxidase isoform, has been identified as a significant contributor to renal ROS in humans. Elevated levels of renal ROS contribute to endothelial cell dysfunction and associated inflammation, causing increased endothelial permeability, which can disrupt the renal ecosystem, leading to progressive albuminuria and renal fibrosis in DKD. This study specifically examines the contribution of endothelial cell-specific human NOX5 expression in renal pathology in a transgenic mouse model of DKD. This study additionally compares NOX5 with the previously characterized NADPH oxidase, NOX4, in terms of their relative roles in DKD. Regardless of NOX4 pathway, this study found that endothelial cell-specific expression of NOX5 exacerbates renal injury, albuminuria and fibrosis. This is attributed to the activation of the endothelial mesenchymal transition (EMT) pathway via enhanced ROS formation and the modulation of redox-sensitive factors. These findings underscore the potential therapeutic significance of NOX5 inhibition in human DKD. The study proposes that inhibiting NOX5 could be a promising approach for mitigating the progression of DKD and strengthens the case for the development of NOX5-specific inhibitors as a potential therapeutic intervention.
| Original language | English |
|---|---|
| Article number | 396 |
| Number of pages | 18 |
| Journal | Antioxidants |
| Volume | 13 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- diabetic kidney disease
- fibrosis
- inflammation
- NOX4
- NOX5
- reactive oxygen species (ROS)
Projects
- 3 Finished
-
Reducing the burden of diabetic complications
Cooper, M. (Primary Chief Investigator (PCI))
1/01/20 → 31/12/24
Project: Research
-
Novel treatments for diabetic complications
Jandeleit-Dahm, K. (Primary Chief Investigator (PCI))
1/01/17 → 31/12/19
Project: Research
-
The role of NADPH oxidase-Nox5 in diabetic kidney disease: in vitro and in vivo studies
Jha, J. (Primary Chief Investigator (PCI))
1/01/17 → 31/12/20
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver